Millennium Pharmaceuticals, Inc.
EARLY ACS trial designed to reinforce benefit of early use of Integrilin
Published in Pharma Law Weekly, July 26th, 2005
The EARLY ACS trial design incorporates new technologies and reflects current treatment patterns in patients with non-ST elevation acute coronary syndromes (nSTE ACS) in a "real-world" setting. nSTE ACS is the term applied to unstable angina and non-ST elevation myocardial infarction (MI).
The trial is designed to provide important evidence regarding the potential benefit of initiating Integrilin, a potent glycoprotein (GP) IIb-IIIa inhibitor, early after patients present with high-risk acute...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly
Source: Pharma Law Weekly (2005-07-26)
More Articles from Pharma Law Weekly
- Chemokine Therapeutics Corp.
U.S. patent allowed for novel cancer drug in clinical development - Frost & Sullivan
Consultancy releases study on pharma industry - Generex Biotechnology Corp.
Drug-delivery company gets Mexican patent - Hacettepe University, Ankara
N-acetylcysteine treatment has no prophylactic use - Medtronic, Inc.
Technology company purchases land for new headquarters, launches online resource - Myriad Genetics, Inc.
Biopharmaceutical company announces patent on amyloid lowering drugs - More from this issue of Pharma Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
